Product Description
for the treatment of critical limb ischemia (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25190335/)
Mechanisms of Action: Gene Therapy,C-Met
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AnGes USA, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Atherosclerosis
Phase 2: Peripheral Arterial Disease|Peripheral Vascular Diseases|Foot Ulcer|Leg Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AG-CLTI-0211 | P2 |
Unknown status |
Leg Ulcer|Peripheral Arterial Disease|Foot Ulcer |
2022-07-01 |
24% |
| JapicCTI-195088 | P3 |
Unknown |
Unknown |
2021-12-31 |
|
| AG-CLI-0206-LTFU | N/A |
Completed |
Other |
2020-01-10 |
|
| 2016-003491-41 | P3 |
Completed |
Unknown |
2020-01-10 |